1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Neurofibromatoses - Pipeline Review, H1 2016

Neurofibromatoses - Pipeline Review, H1 2016

  • June 2016
  • -
  • Global Markets Direct
  • -
  • 73 pages

Neurofibromatoses - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Neurofibromatoses - Pipeline Review, H1 2016’, provides an overview of the Neurofibromatoses pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neurofibromatoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neurofibromatoses
- The report reviews pipeline therapeutics for Neurofibromatoses by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neurofibromatoses therapeutics and enlists all their major and minor projects
- The report assesses Neurofibromatoses therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neurofibromatoses

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neurofibromatoses pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Neurofibromatoses - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2

Introduction 6
Global Markets Direct Report Coverage 6
Neurofibromatoses Overview 7
Therapeutics Development 8
Pipeline Products for Neurofibromatoses - Overview 8
Pipeline Products for Neurofibromatoses - Comparative Analysis 9
Neurofibromatoses - Therapeutics under Development by Companies 10
Neurofibromatoses - Therapeutics under Investigation by Universities/Institutes 11
Neurofibromatoses - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Neurofibromatoses - Products under Development by Companies 14
Neurofibromatoses - Products under Investigation by Universities/Institutes 15
Neurofibromatoses - Companies Involved in Therapeutics Development 16
Alexion Pharmaceuticals, Inc. 16
Arno Therapeutics, Inc. 17
AstraZeneca Plc 18
CalAsia Pharmaceuticals, Inc. 19
Kolltan Pharmaceuticals, Inc. 20
Lixte Biotechnology Holdings, Inc. 21
Novartis AG 22
Pfizer Inc. 23
Neurofibromatoses - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AR-42 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
RandD Progress 33
asfotase alfa - Drug Profile 35
Product Description 35
Mechanism Of Action 35
RandD Progress 35
everolimus - Drug Profile 40
Product Description 40
Mechanism Of Action 40
RandD Progress 40
FRAX-597 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
RandD Progress 50
KTN-0158 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
RandD Progress 51
LB-201 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
RandD Progress 54
LB-205 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
RandD Progress 55
OS-342 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
RandD Progress 56
selumetinib sulfate - Drug Profile 57
Product Description 57
Mechanism Of Action 57
RandD Progress 57
Small Molecules for Neurofibromatoses Type I - Drug Profile 62
Product Description 62
Mechanism Of Action 62
RandD Progress 62
Small Molecules to Inhibit Hsp90-Alpha and TRAP 1 for Neurofibromatosis Type 2 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
RandD Progress 63
sunitinib malate - Drug Profile 64
Product Description 64
Mechanism Of Action 64
RandD Progress 64
Neurofibromatoses - Dormant Projects 69
Neurofibromatoses - Discontinued Products 70
Neurofibromatoses - Product Development Milestones 71
Featured News and Press Releases 71
May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73

List of Tables
Number of Products under Development for Neurofibromatoses, H1 2016 8
Number of Products under Development for Neurofibromatoses - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Neurofibromatoses - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 16
Neurofibromatoses - Pipeline by Arno Therapeutics, Inc., H1 2016 17
Neurofibromatoses - Pipeline by AstraZeneca Plc, H1 2016 18
Neurofibromatoses - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016 19
Neurofibromatoses - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 20
Neurofibromatoses - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 21
Neurofibromatoses - Pipeline by Novartis AG, H1 2016 22
Neurofibromatoses - Pipeline by Pfizer Inc., H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Neurofibromatoses - Dormant Projects, H1 2016 69
Neurofibromatoses - Discontinued Products, H1 2016 70

List of Figures
Number of Products under Development for Neurofibromatoses, H1 2016 8
Number of Products under Development for Neurofibromatoses - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Top 10 Targets, H1 2016 25
Number of Products by Stage and Top 10 Targets, H1 2016 25
Number of Products by Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31

Companies Mentioned
Alexion Pharmaceuticals, Inc.
Arno Therapeutics, Inc.
AstraZeneca Plc
CalAsia Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc.
Lixte Biotechnology Holdings, Inc.
Novartis AG
Pfizer Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK

  • November 2016
    10 pages
  • Cancer  

  • United Kingdom  

View report >

Cervical Cancer Statistics

  • November 2016
    6 pages
  • Cervical Cancer  

    Vaccine  

    HPV Vaccine  

View report >

Pollution Control Statistics in the US

  • November 2016
    218 pages
  • Pollution Contr...  

    Cancer  

    Metals  

  • United States  

    North America  

View report >

Related Market Segments :

Cancer
Therapy
Pharmaceutical
Targeted Therapy

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.